Benitec Biopharma Inc.
BNTCBenitec Biopharma Inc. in brief
Benitec Biopharma Inc. is a listed company in the Biotechnology industry, based in Hayward, California, USA. It was founded in 1997. Its market value was $307 M on 29 October 2026, which makes it the 14,684th largest listed company in the world and the 2,861st largest in the USA on this site. Jerel A. Banks is its chief executive. Its shares trade under the symbol BNTC (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Benitec Biopharma Inc.
Benitec Biopharma Limited is an Australian biotechnology company founded in 1997. It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference (ddRNAi) technology.
The CSIRO has researched RNAi extensively, developing the small hairpin RNA concept employed in ddRNAi. Benitec Biopharma has an exclusive license to this ddRNAi technology in human therapeutic uses and research.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Benitec Biopharma Inc. timeline
- 1997
- 🏁· approximateFounded
- 2015
- 🔔· approximateInitial public offering on Nasdaq
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
Events of Benitec Biopharma Inc. from Wikidata, the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,723 (Jan 2020) · #5,391 (Jan 2022) · #5,759 (Dec 2022) · #4,332 (Jul 2023) · #4,557 (Jan 2024) · #1,376 (Mar 2026) · #2,621 (Aug 2026) · #2,842 (Oct 2026) · #2,865 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.7×
- Free cash flow yield
- -5.4%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -25.7%
- Liabilities / assets
- 3.1%
- Revenue growth
- +14.3%
- R&D / revenue
- 15962.5%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | — | — | $-51M | $-46M | — |
| Jun 2025 | — | — | $-42M | $-38M | — |
| Jun 2024 | — | — | $-22M | $-22M | — |
| Jun 2023 | $0M | +14.3% | $-19M | $-20M | -24450.0% |
| Jun 2022 | $0M | +16.7% | $-18M | $-18M | -26014.3% |
| Jun 2021 | $0M | -40.0% | $-14M | $-14M | -23133.3% |
| Jun 2020 | $0M | -99.2% | $-8M | $-8M | -8270.0% |
| Jun 2019 | $12M | — | $3M | $3M | 21.4% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Jun 2026 | $-17M | $0M | $-17M | $-0.98 | — |
| Jun 2025 | $-24M | $0M | $-24M | $-1.05 | — |
| Jun 2024 | $-19M | $0M | $-20M | $-1.22 | — |
| Jun 2023 | $-18M | $0M | $-18M | $-14.12 | — |
| Jun 2022 | $-16M | $0M | $-16M | $-37.88 | — |
| Jun 2021 | $-13M | $0M | $-13M | $-3.23 | — |
| Jun 2020 | $-8M | $0M | $-8M | $-8.10 | — |
| Jun 2019 | $5M | $0M | $4M | $3.05 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-13M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Oct 28, 20268-KCurrent reportRegulation FD disclosure
- Oct 20, 2026DEF 14AProxy statement
- Oct 5, 20268-KCurrent reportRegulation FD disclosure
- Sep 30, 20268-KCurrent reportAuditor change
- Sep 24, 20268-KCurrent reportAuditor change
- Sep 14, 202610-KAnnual report · period to Jun 2026
- Sep 14, 20268-KCurrent reportResults of operations
- May 29, 20268-KCurrent reportDirectors or officers changed
- May 14, 202610-QQuarterly report · period to Mar 2026
- May 14, 20268-KCurrent reportResults of operations
- Mar 20, 202610-K/AAnnual report (amended) · period to Jun 2025
- Feb 12, 20268-KCurrent reportResults of operations
Official filings of Benitec Biopharma Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-51 M
- Net income
- $-46 M
For year ending June-2026 · source: SEC filing
Balance sheet
- Total assets
- $183 M
- Total liabilities
- $6 M
- Total equity
- $177 M
As of June-2026
Top 91 institutional investors in Benitec Biopharma Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Montanova Capital, LLC | 11,548,351 | 0 (0.00%) | 33.11% | $115 M | Nov 16, 2026 |
| 2 | Franklin Templeton Inc | 2,412,279 | -609 (-0.03%) | 6.92% | $24 M | Nov 12, 2026 |
| 3 | Janus Henderson Group Ltd. | 2,346,047 | — | 6.73% | $23 M | Nov 16, 2026 |
| 4 | Adage Capital Partners GP, L.L.C. | 2,120,672 | 0 (0.00%) | 6.08% | $21 M | Nov 16, 2026 |
| 5 | Ra Capital Management, L.P. | 1,850,000 | 0 (0.00%) | 5.30% | $19 M | Nov 16, 2026 |
| 6 | Nantahala Capital Management, LLC | 1,677,567 | -1,299,175 (-43.64%) | 4.81% | $17 M | Nov 13, 2026 |
| 7 | BlackRock, Inc. | 1,427,861 | +20,723 (+1.47%) | 4.09% | $14 M | Nov 13, 2026 |
| 8 | Infinitum Asset Management, LLC | 1,259,875 | +336,869 (+36.50%) | 3.61% | $13 M | Nov 16, 2026 |
| 9 | Vanguard Capital Management LLC | 1,035,637 | +81,104 (+8.50%) | 2.97% | $10 M | Nov 13, 2026 |
| 10 | Simplify Asset Management Inc. | 1,002,201 | -3,356 (-0.33%) | 2.87% | $10 M | Oct 27, 2026 |
| 11 | Millennium Management LLC | 760,251 | -161,048 (-17.48%) | 2.18% | $8 M | Nov 16, 2026 |
| 12 | Alyeska Investment Group, L.P. | 750,000 | 0 (0.00%) | 2.15% | $8 M | Nov 16, 2026 |
| 13 | Geode Capital Management, LLC | 666,132 | +54,396 (+8.89%) | 1.91% | $7 M | Nov 6, 2026 |
| 14 | Balyasny Asset Management L.P. | 649,954 | -549 (-0.08%) | 1.86% | $6 M | Nov 16, 2026 |
| 15 | Silverarc Capital Management, LLC | 443,109 | -236,717 (-34.82%) | 1.27% | $4 M | Nov 12, 2026 |
| 16 | State Street Corp | 427,515 | +49,542 (+13.11%) | 1.23% | $4 M | Nov 12, 2026 |
| 17 | Ameriprise Financial Inc | 392,991 | -8,254 (-2.06%) | 1.13% | $4 M | Nov 16, 2026 |
| 18 | Citadel Advisors LLC | 271,278 | +189,812 (+233.00%) | 0.78% | $3 M | Nov 16, 2026 |
| 19 | MYDA Advisors LLC | 260,000 | +10,000 (+4.00%) | 0.75% | $3 M | Nov 13, 2026 |
| 20 | Schonfeld Strategic Advisors LLC | 235,525 | +168 (+0.07%) | 0.68% | $2 M | Nov 16, 2026 |
| 21 | Vanguard Fiduciary Trust Co | 198,678 | +37,683 (+23.41%) | 0.57% | $2 M | Nov 13, 2026 |
| 22 | Goldman Sachs Group Inc | 193,550 | +15,509 (+8.71%) | 0.55% | $2 M | Nov 16, 2026 |
| 23 | Northern Trust Corp | 191,849 | +13,415 (+7.52%) | 0.55% | $2 M | Nov 16, 2026 |
| 24 | AWM Investment Company, Inc. | 187,977 | 0 (0.00%) | 0.54% | $2 M | Nov 13, 2026 |
| 25 | Vanguard Portfolio Management LLC | 146,389 | +2,879 (+2.01%) | 0.42% | $1 M | Nov 13, 2026 |
Show all 91: investors 26 to 91
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | UBS Group AG | 109,954 | -15,477 (-12.34%) | 0.32% | $1 M | Nov 10, 2026 |
| 27 | Walleye Capital LLC | 77,984 | New | 0.22% | $1 M | Nov 13, 2026 |
| 28 | Wellington Management Group LLP | 71,196 | New | 0.20% | $1 M | Nov 16, 2026 |
| 29 | Charles Schwab Investment Management Inc | 70,918 | +67 (+0.09%) | 0.20% | $1 M | Nov 16, 2026 |
| 30 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 67,485 | +22,379 (+49.61%) | 0.19% | $1 M | Nov 16, 2026 |
| 31 | Lion Point Capital, LP | 62,000 | 0 (0.00%) | 0.18% | $1 M | Nov 16, 2026 |
| 32 | Bank of New York Mellon Corp | 59,861 | -200 (-0.33%) | 0.17% | $1 M | Nov 5, 2026 |
| 33 | Bank Of America Corp /de/ | 52,580 | +36,609 (+229.22%) | 0.15% | $1 M | Nov 16, 2026 |
| 34 | Atom Investors LP | 48,290 | -301 (-0.62%) | 0.14% | $0 M | Nov 16, 2026 |
| 35 | Cantor Fitzgerald, L. P. | 46,659 | -46,659 (-50.00%) | 0.13% | $0 M | Nov 16, 2026 |
| 36 | Morgan Stanley | 42,893 | +23,317 (+119.11%) | 0.12% | $0 M | Nov 13, 2026 |
| 37 | Nuveen, LLC | 33,403 | +5,064 (+17.87%) | 0.10% | $0 M | Nov 10, 2026 |
| 38 | Woodline Partners LP | 29,118 | New | 0.08% | $0 M | Nov 16, 2026 |
| 39 | XTX Topco Ltd | 28,147 | New | 0.08% | $0 M | Nov 16, 2026 |
| 40 | Rhumbline Advisers | 27,795 | +1,553 (+5.92%) | 0.08% | $0 M | Nov 10, 2026 |
| 41 | Quadrature Capital Ltd | 26,302 | +10,931 (+71.11%) | 0.08% | $0 M | Nov 13, 2026 |
| 42 | AQR Capital Management LLC | 25,051 | +2,570 (+11.43%) | 0.07% | $0 M | Nov 16, 2026 |
| 43 | Canada Pension Plan Investment Board | 23,700 | +6,500 (+37.79%) | 0.07% | $0 M | Nov 16, 2026 |
| 44 | Russell Investments Group, Ltd. | 22,314 | -106,656 (-82.70%) | 0.06% | $0 M | Nov 6, 2026 |
| 45 | Point72 Asset Management, L.P. | 22,211 | New | 0.06% | $0 M | Nov 16, 2026 |
| 46 | American Century Companies Inc | 20,531 | New | 0.06% | $0 M | Nov 12, 2026 |
| 47 | Price T Rowe Associates Inc /MD/ | 18,528 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 48 | Deutsche Bank AG\ | 18,161 | -2,659 (-12.77%) | 0.05% | $0 M | Nov 6, 2026 |
| 49 | Martingale Asset Management L P | 16,150 | 0 (0.00%) | 0.05% | $0 M | Nov 12, 2026 |
| 50 | MetLife Investment Management, LLC | 15,424 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 51 | Creative Planning | 15,327 | New | 0.04% | $0 M | Nov 2, 2026 |
| 52 | Prudential Financial Inc | 14,808 | New | 0.04% | $0 M | Nov 16, 2026 |
| 53 | EntryPoint Capital, LLC | 14,405 | -643 (-4.27%) | 0.04% | $0 M | Nov 13, 2026 |
| 54 | Vanguard Global Advisers, LLC | 12,858 | +4,198 (+48.48%) | 0.04% | $0 M | Nov 13, 2026 |
| 55 | Jpmorgan Chase & Co | 10,496 | +1,500 (+16.67%) | 0.03% | $0 M | Nov 12, 2026 |
| 56 | Invesco Ltd. | 10,251 | -734 (-6.68%) | 0.03% | $0 M | Nov 12, 2026 |
| 57 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 9,872 | New | 0.03% | $0 M | Nov 16, 2026 |
| 58 | Barclays PLC | 8,317 | +4,902 (+143.54%) | 0.02% | $0 M | Nov 6, 2026 |
| 59 | GAMMA Investing LLC | 8,044 | +83 (+1.04%) | 0.02% | $0 M | Oct 8, 2026 |
| 60 | FMR LLC | 6,812 | +1,596 (+30.60%) | 0.02% | $0 M | Nov 10, 2026 |
| 61 | Police & Firemen's Retirement System of New Jersey | 6,806 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 62 | BNP Paribas Financial Markets | 4,871 | +1,489 (+44.03%) | 0.01% | $0 M | Nov 12, 2026 |
| 63 | New York State Common Retirement Fund | 4,327 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 64 | Wells Fargo & Company/mn | 4,280 | -13,662 (-76.15%) | 0.01% | $0 M | Nov 16, 2026 |
| 65 | Tower Research Capital LLC (TRC) | 2,804 | +132 (+4.94%) | 0.01% | $0 M | Nov 16, 2026 |
| 66 | Jones Financial Companies Lllp | 2,417 | +250 (+11.54%) | 0.01% | $0 M | Nov 13, 2026 |
| 67 | Legal & General Group Plc | 2,131 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 68 | Global Retirement Partners, LLC | 1,624 | New | 0.00% | $0 M | Nov 10, 2026 |
| 69 | Ameritas Investment Partners, Inc. | 1,477 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 70 | Royal Bank Of Canada | 1,100 | +464 (+72.96%) | 0.00% | $0 M | Nov 16, 2026 |
| 71 | Citigroup Inc | 1,039 | -8,812 (-89.45%) | 0.00% | $0 M | Nov 4, 2026 |
| 72 | Allworth Financial LP | 551 | +513 (+1350.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 73 | Sterling Capital Management LLC | 437 | +28 (+6.85%) | 0.00% | $0 M | Oct 22, 2026 |
| 74 | California State Teachers Retirement System | 272 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 75 | Farther Finance Advisors, LLC | 243 | +223 (+1115.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 76 | US Bancorp \de\ | 234 | +140 (+148.94%) | 0.00% | $0 M | Nov 5, 2026 |
| 77 | Arax Advisory Partners | 227 | -22 (-8.84%) | 0.00% | $0 M | Nov 12, 2026 |
| 78 | Fifth Third Bancorp | 140 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 79 | PNC Financial Services Group, Inc. | 96 | -138 (-58.97%) | 0.00% | $0 M | Nov 6, 2026 |
| 80 | Group One Trading LLC | 89 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 81 | Caitong International Asset Management Co., Ltd | 25 | +16 (+177.78%) | 0.00% | $0 M | Oct 29, 2026 |
| 82 | EverSource Wealth Advisors, LLC | 22 | -8 (-26.67%) | 0.00% | $0 M | Nov 4, 2026 |
| 83 | Covestor Ltd | 21 | New | 0.00% | $0 M | Oct 30, 2026 |
| 84 | SJS Investment Consulting Inc. | 18 | +16 (+800.00%) | 0.00% | $0 M | Oct 26, 2026 |
| 85 | True Wealth Design, LLC | 18 | -5 (-21.74%) | 0.00% | $0 M | Oct 13, 2026 |
| 86 | Root Financial Partners, LLC | 18 | New | 0.00% | $0 M | Oct 21, 2026 |
| 87 | Essential Partners LLC | 16 | New | 0.00% | $0 M | Oct 14, 2026 |
| 88 | SBI Securities Co., Ltd. | 8 | New | 0.00% | $0 M | Oct 22, 2026 |
| 89 | Provenance Wealth Advisors, LLC | 8 | New | 0.00% | $0 M | Oct 30, 2026 |
| 90 | Rothschild Investment LLC | 5 | -9 (-64.29%) | 0.00% | $0 M | Nov 10, 2026 |
| 91 | Osaic Holdings, Inc. | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
Mutual funds holding Benitec Biopharma Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Simplify Health Care ETFSimplify Asset Management Inc. | 1.01 M | $13 M | 2.9% | 3.8% | +77% | Jun 30, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 995,152 | $12 M | 2.9% | 1.0% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 649,542 | $9 M | 1.9% | <0.01% | +3.5% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 533,504 | $7 M | 1.5% | <0.01% | +19% | Jun 30, 2026 |
| 🇺🇸 Franklin Small Cap Growth FundFranklin Advisers, Inc. | 357,531 | $4 M | 1.0% | 0.17% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 281,899 | $4 M | 0.81% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 233,034 | $3 M | 0.67% | <0.01% | +21% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 188,332 | $3 M | 0.54% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 130,966 | $2 M | 0.38% | <0.01% | +0.4% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 99,969 | $1 M | 0.29% | <0.01% | +36% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 71,527 | $1 M | 0.21% | 0.06% | +47% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 51,745 | $1 M | 0.15% | <0.01% | +22% | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 41,853 | $1 M | 0.12% | <0.01% | +26% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 42,298 | $0 M | 0.12% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 38,625 | $0 M | 0.11% | <0.01% | +8.9% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 28,102 | $0 M | 0.08% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 28,339 | $0 M | 0.08% | <0.01% | +23% | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 21,271 | $0 M | 0.06% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 24,190 | $0 M | 0.07% | <0.01% | +41% | May 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 19,000 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 18,030 | $0 M | 0.05% | 0.01% | +34% | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 12,014 | $0 M | 0.03% | <0.01% | +59% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 11,699 | $0 M | 0.03% | <0.01% | −92% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 13,000 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 11,300 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 11,078 | $0 M | 0.03% | <0.01% | −17% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 11,064 | $0 M | 0.03% | <0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 10,208 | $0 M | 0.03% | 0.06% | no change | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 9,458 | $0 M | 0.03% | 0.01% | +67% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 9,001 | $0 M | 0.03% | <0.01% | −14% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 10,191 | $0 M | 0.03% | <0.01% | +21% | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 8,964 | $0 M | 0.03% | <0.01% | +3.0% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 8,025 | $0 M | 0.02% | <0.01% | +37% | May 31, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 7,730 | $0 M | 0.02% | <0.01% | +1.3% | May 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 6,600 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 5,664 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 4,817 | $0 M | 0.01% | 0.03% | +41% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 4,779 | $0 M | 0.01% | <0.01% | +29% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 4,317 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 3,666 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 3,552 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 4,027 | $0 M | 0.01% | 0.01% | +6.5% | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 3,864 | $0 M | 0.01% | <0.01% | +3.7% | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 3,347 | $0 M | <0.01% | <0.01% | +24% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 3,251 | $0 M | <0.01% | <0.01% | +62% | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 2,974 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 2,763 | $0 M | <0.01% | <0.01% | +59% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 2,721 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 2,338 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 2,496 | $0 M | <0.01% | <0.01% | +56% | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 2,040 | $0 M | <0.01% | <0.01% | +96% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 2,040 | $0 M | <0.01% | <0.01% | +96% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 2,312 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 1,698 | $0 M | <0.01% | 0.01% | +43% | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 1,698 | $0 M | <0.01% | <0.01% | +42% | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 1,890 | $0 M | <0.01% | <0.01% | +51% | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 1,477 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 1,636 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 1,500 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 1,274 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 1,176 | $0 M | <0.01% | <0.01% | −92% | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 1,267 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 1,212 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 938 | $0 M | <0.01% | <0.01% | +82% | Jun 30, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 821 | $0 M | <0.01% | <0.01% | −36% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 912 | $0 M | <0.01% | <0.01% | +42% | May 31, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 751 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 633 | $0 M | <0.01% | <0.01% | −1.1% | Jun 30, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 725 | $0 M | <0.01% | <0.01% | −21% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 714 | $0 M | <0.01% | <0.01% | −22% | May 31, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 616 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 442 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 493 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc. | 127 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 95 | $0 M | <0.01% | <0.01% | −93% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 75 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Benitec Biopharma Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | J. Kevin BuchiDirector | Gift | -51,813 | — | — | 52,097 | Form 4 |
| filed | Aaron CowenDirector, 10% owner | Buyindirect | +65,800 | $13.44 | $884 K | 9.70 M | Form 4 |
| filed | Aaron CowenDirector, 10% owner | Buyindirect | +11,587 | $13.44 | $156 K | 1.85 M | Form 4 |
| filed | Aaron CowenDirector, 10% owner | Buyindirect | +14,320 | $13.10 | $188 K | 9.63 M | Form 4 |
| filed | Aaron CowenDirector, 10% owner | Buyindirect | +2,516 | $13.10 | $33 K | 1.84 M | Form 4 |
| filed | Aaron CowenDirector, 10% owner | Buyindirect | +42,600 | $12.85 | $547 K | 9.62 M | Form 4 |
| filed | Aaron CowenDirector, 10% owner | Buyindirect | +7,400 | $12.85 | $95 K | 1.83 M | Form 4 |
| filed | Averill Madison Master Fund, Ltd.10% owner | Buyindirect | +16,650 | $12.08 | $201 K | 9.58 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Benitec Biopharma Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 10,166 shares at $8.80
- : 8,366 shares at $8.65
- : 2,366 shares at $8.50
- : 285 shares at $8.11
- : 49,715 shares at $8.99
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Benitec Biopharma Inc. scorecard#
Passes 2 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2026; market cap of Oct 29, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.7×Price to book 1.7× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-5.4%Free cash flow is -5.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.98 vs -1.05Diluted EPS -0.98 in fiscal 2026 against -1.05 the year before (report's currency).
- ✗Net income higher than five years earlier-$46 M-$46 M in fiscal 2026 against -$14 M in 2021.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$46 MNet income -$46 M in fiscal 2026.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2026.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-33.2%-33.2% in fiscal 2026.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities34.0×Current ratio 34.02 at the end of fiscal 2026.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2026.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year28.6%Diluted shares up 28.6% in fiscal 2026.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Benitec Biopharma Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2026to Jun 30, 2026 | FY 2025to Jun 30, 2025 | FY 2024to Jun 30, 2024 | FY 2023to Jun 30, 2023 | FY 2022to Jun 30, 2022 | FY 2021to Jun 30, 2021 | FY 2020to Jun 30, 2020 | FY 2019to Jun 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | — | 0−100%— | 0.1+2.7%100% | 0.1+23.7%100% | 0.1−42.2%100% | 0.1−99.2%100% | 12—100% | |
| Research and development | 23+27.6%— | 18+17.4%— | 16+22.2%— | 13+13.3%17032% | 11+60.6%15441% | 7.0+134%11898% | 3.0−34.3%2942% | 4.6—37.4% | |
| General and administrative | 28+18.7%— | 23+235%— | 7.0+9.5%— | 6.4−4.0%8509% | 6.6+2.1%9104% | 6.5+17.0%11037% | 5.6+20.7%5458% | 4.6—37.8% | |
| Operating expenses | 51+22.6%— | 42+85.7%— | 22+17.4%— | 19+6.9%25541% | 18+31.3%24558% | 14+62.9%23144% | 8.4−12.8%8219% | 9.6—78.8% | |
| Operating income | −51—— | −42—— | −22—— | −19—−25441% | −18—−24458% | −14—−23044% | −8.3−421%−8119% | 2.6—21.2% | |
| Other non-operating income (expense) | 5.6+46.7%— | 3.8+421%— | 0.7—— | −0.5—−641% | −0.4—−485% | −0.3−4186%−485% | 0.0−73.1%6.9% | 0.0—0.2% | |
| Income tax | 0—— | — | — | — | — | — | — | — | |
| Net income attributable to shareholders | −46—— | −38—— | −22—— | −20—−26083% | −18—−24942% | −14—−23529% | −8.3−417%−8112% | 2.6—21.4% | |
| Earnings per share, basic | -0.98—— | -1.05—— | -1.22r-5.51—— | -14.12—— | -37.88r-2.23—— | -3.23—— | -8.10−366%— | 3.05—— | |
| Earnings per share, diluted | -0.98—— | -1.05—— | -1.22r-5.51—— | -14.12—— | -37.88r-2.23—— | -3.23—— | -8.10−366%— | 3.05—— | |
| Shares, weighted average (basic) | 47+28.6%— | 36+97.2%— | 18r4.1+1225%— | 1.4+188%— | 0.5r8.2−88.8%— | 4.3—— | — | — | |
| Shares, weighted average (diluted) | 47+28.6%— | 36+97.2%— | 18r4.1+1225%— | 1.4+188%— | 0.5r8.2−88.8%— | 4.3+321%— | 1.0+19.2%— | 0.9—— | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 180+84.1%98.5% | 98+92.2%98.1% | 51+1954%97.4% | 2.5−39.0%55.5% | 4.1−79.5%68.0% | 20+102%92.5% | 9.8−37.6%84.6% | 16—81.7% | |
| Other current assets | 1.6+154%0.9% | 0.6+21.7%0.6% | 0.5−56.4%1.0% | 1.2+59.8%26.5% | 0.7−7.3%12.4% | 0.8r0.8−15.8%3.7% | 0.9+89.0%8.2% | 0.5—2.6% | |
| Current assets | 182+84.4%99.5% | 99+90.7%98.9% | 52+1286%99.0% | 3.7−22.6%83.5% | 4.8−76.6%80.7% | 21+90.7%96.4% | 11−42.4%93.3% | 19—97.5% | |
| Property, plant and equipment | 0.2+35.9%0.1% | 0.1−26.8%0.1% | 0.2+106%0.3% | 0.1−60.8%1.9% | 0.2−40.8%3.7% | 0.4+0.3%1.8% | 0.4−20.4%3.2% | 0.5—2.4% | |
| Right-of-use (leased) assets | 0.7−19.4%0.4% | 0.9+219%0.9% | 0.3−48.7%0.5% | 0.5−31.8%11.8% | 0.80.0%12.9% | 0.8r0.2+95.2%3.6% | 0.4—3.4% | — | |
| Total assets | 183+83.4%100% | 100+90.8%100% | 52+1070%100% | 4.5−25.3%100% | 6.0−72.1%100% | 21+84.5%100% | 12−39.8%100% | 19—100% | |
| Accounts payable | 0.9+354%0.5% | 0.2−85.1%0.2% | 1.4+18.5%2.6% | 1.1+170%25.5% | 0.4+54.0%7.1% | 0.3−2.8%1.3% | 0.3−80.9%2.4% | 1.5—7.7% | |
| Current liabilities | 5.3+197%2.9% | 1.8−63.4%1.8% | 4.9+23.8%9.4% | 4.0+57.1%89.1% | 2.5+85.0%42.4% | 1.4+20.5%6.4% | 1.1−57.0%9.8% | 2.6—13.7% | |
| Lease liabilities (non-current) | 0.3−46.3%0.1% | 0.5—0.5% | 0−100%0.0% | 0.3−49.2%6.4% | 0.6—9.4% | 0−100%0.0% | 0.2—1.8% | — | |
| Total liabilities | 5.6+144%3.1% | 2.3−53.7%2.3% | 5.0+16.4%9.5% | 4.3+37.9%95.5% | 3.1+126%51.7% | 1.4+1.5%6.4% | 1.3−48.9%11.6% | 2.6—13.7% | |
| Retained earnings | −274—−150% | −228—−229% | −190—−364% | −168—−3761% | −148—−2483% | −130—−609% | −117—−1007% | −109—−566% | |
| Shareholders' equity | 177+81.9%96.9% | 97+106%97.7% | 47+23290%90.5% | 0.2−93.0%4.5% | 2.9−85.6%48.3% | 20+95.4%93.6% | 10−38.3%88.4% | 17—86.3% | |
| Total liabilities and equity | 183+83.4%100% | 100+90.8%100% | 52+1070%100% | 4.5−25.3%100% | 6.0−72.1%100% | 21+84.5%100% | 12−39.8%100% | 19—100% | |
| Shares outstanding | 34+31.1%— | 26+160%— | 10r1.7+503%— | 1.7r1.6+248%— | 0.5r8.2−94.1%— | 8.2+637%— | 1.1+29.4%— | 0.9—— | |
| Cash-flow statement | |||||||||
| Depreciation and amortization | 0.1−12.1%— | 0.1−24.1%— | 0.1−36.0%— | 0.1−18.6%181% | 0.2−27.7%229% | 0.2+21.6%392% | 0.2+20.3%186% | 0.2—1.3% | |
| Share-based compensation | 26+51.6%— | 17+2000%— | 0.8+83.6%— | 0.5−48.0%603% | 0.9+37.2%1192% | 0.6+168%1075% | 0.2−64.7%232% | 0.7—5.5% | |
| Cash from operating activities | −17—— | −24—— | −19—— | −18—−24016% | −16—−21779% | −13—−21749% | −7.5−257%−7387% | 4.8—39.3% | |
| Capital expenditure | −0.1—— | −0.0—— | −0.2—— | −0.0—−1.3% | −0.0—−17.8% | −0.2—−375% | −0.1—−93.1% | −0.4—−3.3% | |
| Cash from investing activities | −0.1—— | −0.0—— | −0.2—— | −0.0—−1.3% | −0.0—−17.8% | −0.2—−375% | −0.1—−92.2% | −0.4—−3.3% | |
| Shares issued | 104+243%— | 30—— | — | 18—23845% | — | 26+1044%43644% | 2.3—2206% | — | |
| Cash from financing activities | 99+40.4%— | 70+3.6%— | 68+325%— | 16—21353% | — | 23+1172%38173% | 1.8—1735% | — | |
| Exchange-rate effect on cash | — | — | — | — | — | 0.5—846% | −0.1—−56.9% | −0.6—−4.5% | |
| Change in cash | 82+75.2%— | 47−3.1%— | 48—— | −1.6—−2115% | −16−258%−21518% | 10.0—16895% | — | — | |
| Report | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q1 FY2027to Sep 30, 2026 | Q4 FY2026to Jun 30, 2026 | Q3 FY2026to Mar 31, 2026 | Q2 FY2026to Dec 31, 2025 | Q1 FY2026to Sep 30, 2025 | Q4 FY2025to Jun 30, 2025 | Q3 FY2025to Mar 31, 2025 | Q2 FY2025to Dec 31, 2024 | Q1 FY2025to Sep 30, 2024 | Q4 FY2024to Jun 30, 2024 | Q3 FY2024to Mar 31, 2024 | Q2 FY2024to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | 0—— | 0—— | 0—— | — | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | |
| Research and development | 29+58.1%— | 8.6+156%— | 7.9*+175%— | 6.3−3.0%— | 5.8+8.3%— | 3.4−6.0%— | 2.9−18.4%— | 6.5r6.0+153%— | 5.4r5.1+5.5%— | 3.6—— | 3.5*—— | 2.6—— | 5.1—— | |
| General and administrative | 27−1.6%— | 5.9−8.9%— | 6.5*−6.1%— | 7.3−17.6%— | 7.5+39.2%— | 6.4+192%— | 7.0+242%— | 8.8r4.2+460%— | 5.4r3.5+197%— | 2.2—— | 2.0*—— | 1.6—— | 1.8—— | |
| Operating expenses | 56+22.0%— | 14+47.7%— | 14*+46.7%— | 14−11.4%— | 13+23.8%— | 9.8+69.3%— | 9.8+77.3%— | 15r10+270%— | 11r8.6+56.0%— | 5.8—— | 5.5*—— | 4.1—— | 6.9—— | |
| Operating income | −56—— | −14—— | −14*—— | −14—— | −13—— | −9.8—— | −9.8—— | −15r−10—— | −11r−8.6—— | −5.8—— | −5.5*—— | −4.1—— | −6.9—— | |
| Other non-operating income (expense) | 6.4+60.8%— | 1.6+85.2%— | 1.6*+57.5%— | 1.6+97.5%— | 1.5+22.9%— | 0.8+14.5%— | 1.0+24.3%— | 0.8—— | 1.3+871%— | 0.7—— | 0.8*—— | −0.1—— | 0.1—— | |
| Net income attributable to shareholders | −50—— | −13—— | −13*—— | −12—— | −12—— | −9.0—— | −8.8—— | −15r−9.4—— | −9.6r−7.4—— | −5.1—— | −4.7*—— | −4.3—— | −6.8—— | |
| Earnings per share, basic | — | -0.26—— | — | -0.24—— | -0.26—— | -0.22—— | -0.21—— | -0.38r-0.24—— | -0.26r-0.33—— | -0.18r-0.48—— | — | -0.23r-1.64—— | -2.64—— | |
| Earnings per share, diluted | — | -0.26—— | — | -0.24—— | -0.26—— | -0.22—— | -0.21—— | -0.38r-0.24—— | -0.26r-0.33—— | -0.18r-0.48—— | — | -0.23r-1.64—— | -2.64—— | |
| Shares, weighted average (basic) | 49+19.2%— | 49+19.2%— | — | 49+27.9%— | 46+23.4%— | 42+48.9%— | 41—— | 39+111%— | 37r22+1346%— | 28r11—— | — | 18r2.6—— | 2.6—— | |
| Shares, weighted average (diluted) | 49+19.2%— | 49+19.2%— | — | 49+27.9%— | 46+23.4%— | 42+48.9%— | 41—— | 39+111%— | 37r22+1346%— | 28r11—— | — | 18r2.6—— | 2.6—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 176—98.5% | 176+86.7%98.5% | 180+84.1%98.5% | 185+78.4%98.8% | 189+141%99.0% | 94+39.3%98.4% | 98+92.2%98.1% | 104+635%98.5% | 78+284%99.0% | 68—98.6% | 51—97.4% | 14—94.0% | 20—95.4% | |
| Other current assets | 1.6—0.9% | 1.6+238%0.9% | 1.6+154%0.9% | 1.1+216%0.6% | 0.6+53.6%0.3% | 0.5+12.7%0.5% | 0.6+21.7%0.6% | 0.4+130%0.3% | 0.4+3.1%0.5% | 0.4—0.6% | 0.5—1.0% | 0.2—1.0% | 0.4—1.7% | |
| Current assets | 178—99.4% | 178+87.3%99.4% | 182+84.4%99.5% | 186+78.8%99.5% | 190+141%99.4% | 95+39.1%99.0% | 99+90.7%98.9% | 104+624%98.9% | 79+279%99.6% | 68—99.4% | 52—99.0% | 14—95.8% | 21—97.4% | |
| Property, plant and equipment | 0.1—0.1% | 0.1−6.8%0.1% | 0.2+35.9%0.1% | 0.1−20.0%0.1% | 0.1−23.8%0.1% | 0.1−23.4%0.1% | 0.1−26.8%0.1% | 0.1−28.9%0.1% | 0.2+196%0.2% | 0.2—0.2% | 0.2—0.3% | 0.2—1.4% | 0.1—0.2% | |
| Right-of-use (leased) assets | 0.6—0.3% | 0.6−22.5%0.3% | 0.7−19.4%0.4% | 0.8−17.0%0.4% | 0.9+561%0.5% | 0.8+270%0.8% | 0.9+219%0.9% | 1.0+188%0.9% | 0.1−65.8%0.2% | 0.2—0.3% | 0.3—0.5% | 0.3—2.2% | 0.4—1.9% | |
| Total assets | 179—100% | 179+86.5%100% | 183+83.4%100% | 187+77.7%100% | 191+141%100% | 96+39.6%100% | 100+90.8%100% | 105+601%100% | 79+270%100% | 69—100% | 52—100% | 15—100% | 21—100% | |
| Accounts payable | 1.0—0.6% | 1.0+278%0.6% | 0.9+354%0.5% | 0.6+46.7%0.3% | 1.0+71.3%0.5% | 0.3−70.0%0.3% | 0.2−85.1%0.2% | 0.4−46.9%0.4% | 0.6−77.4%0.7% | 0.9—1.3% | 1.4—2.6% | 0.8—5.4% | 2.6—12.3% | |
| Current liabilities | 9.1—5.1% | 9.1+348%5.1% | 5.3+197%2.9% | 3.3−53.4%1.8% | 2.8−9.3%1.5% | 2.0−55.5%2.1% | 1.8−63.4%1.8% | 7.0+104%6.7% | 3.1−46.2%3.9% | 4.6—6.6% | 4.9—9.4% | 3.4—22.9% | 5.7—26.9% | |
| Lease liabilities (non-current) | 0.1—0.1% | 0.1−66.5%0.1% | 0.3−46.3%0.1% | 0.4−35.7%0.2% | 0.5—0.3% | 0.4—0.4% | 0.5—0.5% | 0.6+889%0.6% | 0−100%0.0% | 0—0.0% | 0—0.0% | 0.1—0.4% | 0.1—0.6% | |
| Total liabilities | 9.5—5.3% | 9.5+289%5.3% | 5.6+144%3.1% | 3.7−52.0%2.0% | 3.3+6.2%1.7% | 2.4−47.1%2.5% | 2.3−53.7%2.3% | 7.6+118%7.3% | 3.1−46.8%4.0% | 4.6—6.7% | 5.0—9.5% | 3.5—23.3% | 5.9—27.6% | |
| Retained earnings | −287—−160% | −287—−160% | −274—−150% | −261—−140% | −249—−131% | −237—−247% | −228—−229% | −212—−202% | −203—−256% | −195—−284% | −190—−364% | −186r−185—−1237% | −181r−181—−849% | |
| Shareholders' equity | 170—94.7% | 170+81.2%94.7% | 177+81.9%96.9% | 183+87.9%98.0% | 187+147%98.3% | 94+45.8%97.5% | 97+106%97.7% | 98+748%92.7% | 76+391%96.0% | 64—93.3% | 47—90.5% | 12—76.7% | 15—72.4% | |
| Total liabilities and equity | 179—100% | 179+86.5%100% | 183+83.4%100% | 187+77.7%100% | 191+141%100% | 96+39.6%100% | 100+90.8%100% | 105+601%100% | 79+270%100% | 69—100% | 52—100% | 15—100% | 21—100% | |
| Shares outstanding | 35—— | 35+32.9%— | 34+31.1%— | 34+34.5%— | 34+46.1%— | 26+46.7%— | 26+160%— | 26+838%— | 23+805%— | 18—— | 10r1.7—— | 2.7—— | 2.6—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1+14.8%— | 0.0+30.8%— | 0.0*+21.4%— | 0.0+7.7%— | 0.00.0%— | 0.0−48.0%— | 0.0*−46.2%— | 0.0−48.0%— | 0.0−17.6%— | 0.0—— | 0.0*—— | 0.0—— | 0.0—— | |
| Share-based compensation | 27+20.6%— | 5.5+6.3%— | 6.3*+2.5%— | 7.6−2.0%— | 7.4+135%— | 5.2+1091%— | 6.1r13*+1246%— | 7.7r2.6+3933%— | 3.1r0.9+3274%— | 0.4—— | 0.5*—— | 0.2—— | 0.1—— | |
| Cash from operating activities | −17—— | −3.6—— | −4.9*—— | −4.5*—— | −3.8*—— | −3.4—— | −8.2*—— | −3.1*—— | −7.7*—— | −4.6—— | −3.3*—— | −6.2*—— | −5.4*—— | |
| Capital expenditure | — | — | −0.1*—— | −0.0*—— | — | — | 0*—— | −0.0*—— | — | — | 0*—— | — | — | |
| Cash from investing activities | −0.1—— | 0—— | −0.1*—— | −0.0*—— | −0.0*—— | 0—— | 0*—— | −0.0*—— | −0.0*—— | 0—— | 0*—— | −0.2*—— | 0*—— | |
| Shares issued | — | — | 0*−100%— | 0*−100%— | — | — | 0.0*—— | 30*—— | — | — | — | — | — | |
| Cash from financing activities | 99+103%— | 0—— | 0.2*−91.2%— | 0.5*−98.2%— | 98*+450%— | 0−100%— | 2.7r2.5*−93.2%— | 28r28*—— | 18r18*+45721%— | 22r22—— | 40*—— | 0*—— | 0.0*—— | |
| Change in cash | 82+207%— | −3.6—— | −4.8*—— | −4.0*−116%— | 94*+803%— | −3.3−119%— | −5.6r−5.8*−115%— | 25r25*—— | 10*—— | 17—— | 37*—— | −6.2*—— | −5.5*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K/A | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Benitec Biopharma Inc. operates: 3 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 8 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office5 subsidiaries | — |
| 🇦🇺 Australia | 1 office2 subsidiaries | — |
| 🇬🇧 UK | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Benitec Biopharma Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2026Dr. Jerel A | $6.5 M | $9.5 M | $4.9 M | $330 |
| 2025Dr. Jerel A | $25.9 M | $26.7 M | $6.2 M | $289 |
| 2024Dr. Jerel A | $3.2 M | $4.3 M | $1.4 M | $172 |
Source: SEC proxy statement (Form DEF 14A) · as of Jun 30, 2026
Events at Benitec Biopharma Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Financial statements withdrawn 1 · Auditor changed 2 · Directors and officers 5 · Material agreement 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Auditor changed | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Financial statements withdrawn | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K/A | |
| Directors and officers | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Sep 30, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2024 | $40 M | Private placement after listing | $10 to $50 million | 17 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Benitec Biopharma Inc. compares in Biotechnology
- Market cap$307 M · higher than 51% of 726
- Revenue growth14.3% · higher than 57% of 438
- Price / book1.7× · lower than 62% of 534
- FCF yield-5.4% · higher than 71% of 449
- 🇺🇸 Yarrow Bioscience, Inc.$307 M
- 🇺🇸 Prelude Therapeutics Incorporated$311 M
- 🇰🇷 Prestige Biopharma Limited$311 M
- 🇩🇪 InflaRx N.V.$301 M
- 🇮🇪 Amarin Corporation$297 M
- 🇺🇸 Vogenx, Inc.$296 M
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Benitec Biopharma Inc.🇺🇸 | $307 M | — | — | +14.3% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending June-2026
- Balance sheet:
- As of June-2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, Wikidata, value.today research, Wikipedia; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Benitec Biopharma Inc.? Verify and update this profile — free
Show Benitec Biopharma Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.